The Politics Of Mega-Mergers: Health Care Reform And U.S. Biopharma Realignment
This article was originally published in The Pink Sheet Daily
Merck/Schering, Pfizer/Wyeth underscore sense of long-term structural change in U.S. pharma market.
You may also be interested in...
Jon Leibowitz, a fierce opponent of reverse settlements between brand name and generic companies, is set to head the Federal Trade Commission
$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.
Medicaid rebate increase and follow-on biologics could take $70 billion from pharma over 10 years, key staffer says—but industry should be happy with that trade.